Evusheld from AstraZeneca (tixagevimab and cilgavimab), a combination of long-acting antibodies for the prevention of Covid-19, maintains the neutralizing activity against the ómicron variant SARS-CoV-2 (B.1.1.529), based on new preclinical data.
Evusheld is the only antibody licensed in the United States for covid-19 pre-exposure prophylaxis. It has shown its effectiveness against the omicron variant and retains activity against all variants of interest to date.
Preclinical data from an independent FDA study showed that Evusheld’s inhibitory concentration 50 (IC50), a measure of the neutralizing potency of an antibody, was 171 ng / ml and 277 ng / ml in two confirmatory tests, which is within the range of neutralizing levels found in someone who has previously been infected with COVID-19. The Evusheld IC50 for the parent strain of SARS-CoV-2, formerly known as the Wuhan strain, was approximately 1.3 ng / ml and 1.5 ng / ml, respectively.
Mene PangalosAstraZeneca’s Executive Vice President of R&D for BioPharmaceuticals, explained that “Evusheld was designed to evade potential resistance with the emergence of new variants of SARS-CoV-2.”
“Evusheld is the first long-acting antibody to receive emergency use authorization in the United States for pre-exposure prophylaxis of COVID-19, in addition to authorizations in other countries, and we are working with regulators on applications for the use of Evusheld in the treatment of Covid-19 “.
Finanzas.com is not responsible for the veracity or accuracy of this or any other related information